267 related articles for article (PubMed ID: 22873215)
21. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
22. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
Yegin EG; Oymaci E; Karatay E; Coker A
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma.
He Y; Meng XM; Huang C; Wu BM; Zhang L; Lv XW; Li J
Cancer Lett; 2014 Mar; 344(1):20-27. PubMed ID: 24183851
[TBL] [Abstract][Full Text] [Related]
24. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
[TBL] [Abstract][Full Text] [Related]
25. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.
Shi Q; Chu Q; Zeng Y; Yuan X; Wang J; Zhang Y; Xue C; Li L
Cell Commun Signal; 2023 Dec; 21(1):359. PubMed ID: 38111040
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of non-coding RNAs in cancer.
Slaby O; Laga R; Sedlacek O
Biochem J; 2017 Dec; 474(24):4219-4251. PubMed ID: 29242381
[TBL] [Abstract][Full Text] [Related]
27. RNA interference-mediated prevention and therapy for hepatocellular carcinoma.
Romano PR; McCallus DE; Pachuk CJ
Oncogene; 2006 Jun; 25(27):3857-65. PubMed ID: 16799627
[TBL] [Abstract][Full Text] [Related]
28. Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma.
Plissonnier ML; Herzog K; Levrero M; Zeisel MB
Viruses; 2018 Oct; 10(11):. PubMed ID: 30380697
[TBL] [Abstract][Full Text] [Related]
29. The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention.
Zou H; Shao CX; Zhou QY; Zhu GQ; Shi KQ; Braddock M; Huang DS; Zheng MH
Expert Rev Gastroenterol Hepatol; 2016; 10(3):331-40. PubMed ID: 26558504
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma.
Parasramka MA; Maji S; Matsuda A; Yan IK; Patel T
Pharmacol Ther; 2016 May; 161():67-78. PubMed ID: 27013343
[TBL] [Abstract][Full Text] [Related]
31. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
Vilchez V; Turcios L; Marti F; Gedaly R
World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma.
Umeda S; Kanda M; Kodera Y
Expert Rev Mol Diagn; 2019 Aug; 19(8):725-738. PubMed ID: 31248309
[No Abstract] [Full Text] [Related]
33. Role of miRNA sponges in hepatocellular carcinoma.
Li D; Zhang J; Li J
Clin Chim Acta; 2020 Jan; 500():10-19. PubMed ID: 31604064
[TBL] [Abstract][Full Text] [Related]
34. Current discovery strategies for hepatocellular carcinoma therapeutics.
Dai Q; Zhang C; Yuan Z; Sun Q; Jiang Y
Expert Opin Drug Discov; 2020 Feb; 15(2):243-258. PubMed ID: 31809618
[No Abstract] [Full Text] [Related]
35. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
Wei L; Wang X; Lv L; Liu J; Xing H; Song Y; Xie M; Lei T; Zhang N; Yang M
Mol Cancer; 2019 Oct; 18(1):147. PubMed ID: 31651347
[TBL] [Abstract][Full Text] [Related]
36. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.
Panzitt K; Tschernatsch MM; Guelly C; Moustafa T; Stradner M; Strohmaier HM; Buck CR; Denk H; Schroeder R; Trauner M; Zatloukal K
Gastroenterology; 2007 Jan; 132(1):330-42. PubMed ID: 17241883
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNAs as biomarkers and therapeutic targets: Recent insights into hepatocellular carcinoma.
Qiu L; Tang Q; Li G; Chen K
Life Sci; 2017 Dec; 191():273-282. PubMed ID: 28987633
[TBL] [Abstract][Full Text] [Related]
38. The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action.
Shi X; Zhu HR; Liu TT; Shen XZ; Zhu JM
Cancer Lett; 2017 Aug; 400():175-182. PubMed ID: 28461246
[TBL] [Abstract][Full Text] [Related]
39. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
